EGFR and lung adenocarcinoma: Here, we report a case of pretreated advanced lung adenocarcinoma with EGFR ex20ins (NM_005228: exon 20:c.2316_2321dup: p.773_774dup) benefiting from combined furmonertinib, a novel third-generation EGFR-TKI, with anlotinib, a novel multi-targeting tyrosine kinase inhibitor, for a long time.